Eyegate Pharmaceuticals Company Profile (NASDAQ:EYEG)

About Eyegate Pharmaceuticals

Eyegate Pharmaceuticals logoEyegate Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company's lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System. The Company is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and/or ciliary body, and macular edema, an abnormal thickening of the macula associated with the accumulation of excess fluids in the extracellular space of the neurosensory retina. The EyeGate II Delivery System is designed to deliver optimal quantities of drugs to the anterior or posterior segments of the eye.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: EYEG
  • CUSIP:
Key Metrics:
  • Previous Close: $1.77
  • 50 Day Moving Average: $2.15
  • 200 Day Moving Average: $2.95
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.90
  • P/E Growth: 0.00
  • Market Cap: $16.02M
  • Outstanding Shares: 8,951,000
  • Beta: 2.76
Additional Links:
Companies Related to Eyegate Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Eyegate Pharmaceuticals (NASDAQ:EYEG) (?)
Ratings Breakdown: 1 Hold Rating, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $9.00 (402.79% upside)

Analysts' Ratings History for Eyegate Pharmaceuticals (NASDAQ:EYEG)
Show:
DateFirmActionRatingPrice TargetDetails
6/28/2016Maxim GroupReiterated RatingHoldView Rating Details
6/13/2016Rodman & RenshawReiterated RatingBuyView Rating Details
4/14/2016Chardan CapitalReiterated RatingBuyView Rating Details
4/7/2016Noble FinancialInitiated CoverageBuy -> Buy$10.00View Rating Details
2/1/2016HC WainwrightReiterated RatingBuyView Rating Details
(Data available from 8/26/2014 forward)

Earnings

Earnings History for Eyegate Pharmaceuticals (NASDAQ:EYEG)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Eyegate Pharmaceuticals (NASDAQ:EYEG)
Current Year EPS Consensus Estimate: $-1.64 EPS
Next Year EPS Consensus Estimate: $-0.94 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.32)($0.32)($0.32)
Q2 20161($0.33)($0.33)($0.33)
Q3 20161($0.34)($0.34)($0.34)
Q4 20161($0.35)($0.35)($0.35)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Eyegate Pharmaceuticals (NASDAQ:EYEG)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Eyegate Pharmaceuticals (NASDAQ:EYEG)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/15/2016Morton GoldbergDirectorSell15,000$3.16$47,400.00View SEC Filing  
6/10/2016Ventech Capital IiMajor ShareholderSell28,600$3.04$86,944.00View SEC Filing  
6/8/2016Ventech Capital IiMajor ShareholderSell29,400$3.25$95,550.00View SEC Filing  
6/7/2016Morton GoldbergDirectorSell10,939$3.31$36,208.09View SEC Filing  
2/19/2015(Innoven Partenaires S.A. IpsaMajor ShareholderBuy366,667$6.00$2,200,002.00View SEC Filing  
2/19/2015Paul G ChaneyDirectorBuy8,333$6.00$49,998.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Eyegate Pharmaceuticals (NASDAQ:EYEG)
DateHeadline
kcregister.com logoToday's Watch List: Eyegate Pharmaceuticals (NASDAQ:EYEG ... - KC Register (NASDAQ:EYEG)
www.kcregister.com - August 23 at 5:03 PM
finance.yahoo.com logoEYEGATE PHARMACEUTICALS INC Financials (NASDAQ:EYEG)
finance.yahoo.com - August 23 at 5:03 PM
investornewswire.com logoWill Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) Hit $10 Price Target? - Investor Newswire (NASDAQ:EYEG)
www.investornewswire.com - August 22 at 9:35 AM
reuters.com logoBRIEF-Eyegate Pharma Q2 net loss $3.823 million - Reuters (NASDAQ:EYEG)
www.reuters.com - August 11 at 6:12 AM
globenewswire.com logoEyeGate Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business Update - GlobeNewswire (press release) (NASDAQ:EYEG)
globenewswire.com - August 11 at 6:12 AM
biz.yahoo.com logoEYEGATE PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report (NASDAQ:EYEG)
biz.yahoo.com - August 10 at 5:08 PM
finance.yahoo.com logoEyeGate Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business Update (NASDAQ:EYEG)
finance.yahoo.com - August 10 at 5:08 PM
News Icon2 Biotech Stocks News And Price Trends: Eyegate Pharmaceuticals (NASDAQ:EYEG), Halozyme Therapeutics ... - The Voice Registrar (NASDAQ:EYEG)
voiceregistrar.com - August 2 at 5:07 PM
streetupdates.com logoLast Analysts Rating Review: Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) , Eyegate Pharmaceuticals, Inc ... - Street Updates (NASDAQ:EYEG)
www.streetupdates.com - August 2 at 5:07 PM
reuters.com logoBRIEF-Eyegate Pharmaceuticals reports positive top-line data - Reuters (NASDAQ:EYEG)
www.reuters.com - August 2 at 5:07 PM
News IconBiotechnology Stocks in Limelight: Inotek Pharmaceuticals Corp (NASDAQ:ITEK), Eyegate Pharmaceuticals Inc ... - Post Registrar (NASDAQ:EYEG)
postregistrar.com - August 2 at 5:07 PM
fortune.com logoAnalysts: Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) stock is worth $8.67 - Review Fortune (NASDAQ:EYEG)
reviewfortune.com - August 2 at 5:07 PM
schaeffersresearch.com logoBiotech Stocks Start Off August with a Bang (NASDAQ:EYEG)
www.schaeffersresearch.com - August 1 at 4:52 PM
finance.yahoo.com logoEyeGate Announces Positive Top-line Data from Phase 1b/2a Clinical Trial of EGP-437 for Treatment of … (NASDAQ:EYEG)
finance.yahoo.com - August 1 at 9:45 AM
biz.yahoo.com logoEYEGATE PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:EYEG)
biz.yahoo.com - August 1 at 8:32 AM
investornewswire.com logoIs $10 Price Target Attainable For Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG)? - Investor Newswire (NASDAQ:EYEG)
www.investornewswire.com - July 24 at 4:44 PM
News IconEyegate Pharmaceuticals Incorporated (NASDAQ:EYEG) Shorts Decreased by 4.26% After Short Covering - Press Telegraph (NASDAQ:EYEG)
presstelegraph.com - July 21 at 8:28 AM
investornewswire.com logoStrong Sell Calls For Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) At 0 - Investor Newswire (NASDAQ:EYEG)
www.investornewswire.com - July 19 at 11:03 AM
ftsenews.co.uk logoNew Broker Ratings For Eyegate Pharmaceuticals, Inc. (EYEG) - FTSE News (NASDAQ:EYEG)
www.ftsenews.co.uk - July 16 at 8:21 AM
News IconEyegate Pharmaceuticals Incorporated (NASDAQ:EYEG) Sellers Covered 22.05% of Their Shorts - Consumer Eagle (NASDAQ:EYEG)
www.consumereagle.com - July 15 at 6:50 AM
News IconEyegate Pharmaceuticals Incorporated (NASDAQ:EYEG) Sellers Covered 22.05% of Their Shorts - Engelwood Daily (NASDAQ:EYEG)
www.engelwooddaily.com - July 10 at 4:41 PM
investornewswire.com logoIs $10 Within Reach For Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG)? - Investor Newswire (NASDAQ:EYEG)
www.investornewswire.com - July 10 at 4:41 PM
News IconStock Dipping Down in Session: Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) - Telanagana Press (NASDAQ:EYEG)
telanaganapress.com - July 6 at 10:45 PM
News IconIncreased Volatility Watch for: Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) - Engelwood Daily (NASDAQ:EYEG)
www.engelwooddaily.com - July 6 at 10:45 PM
investornewswire.com logoEyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) Expected to Reach Highs Of $10 - Investor Newswire (NASDAQ:EYEG)
www.investornewswire.com - July 4 at 9:48 AM
News IconCompany Stock Lower on the Week Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) - Engelwood Daily (NASDAQ:EYEG)
www.engelwooddaily.com - July 3 at 9:29 AM
globenewswire.com logoEyeGate Announces Completion of $3.77 Million Registered Direct Offering - GlobeNewswire (press release) (NASDAQ:EYEG)
globenewswire.com - July 2 at 6:04 AM
biz.yahoo.com logoEYEGATE PHARMACEUTICALS INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Othe (NASDAQ:EYEG)
biz.yahoo.com - June 30 at 2:07 PM
finance.yahoo.com logoEyeGate Announces Completion of $3.77 Million Registered Direct Offering (NASDAQ:EYEG)
finance.yahoo.com - June 30 at 1:00 PM
News IconStock Volatility in Review: Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) - Engelwood Daily (NASDAQ:EYEG)
www.engelwooddaily.com - June 29 at 7:17 AM
News IconEyegate Pharmaceuticals Inc (NASDAQ:EYEG)'s Company Shares Decreased 16.44% After High Volatility - Engelwood Daily (NASDAQ:EYEG)
www.engelwooddaily.com - June 29 at 7:17 AM
investing.com logoU.S. stocks lower at close of trade; Dow Jones Industrial Average down 1.50% (NASDAQ:EYEG)
www.investing.com - June 27 at 4:52 PM
reuters.com logoBRIEF-Eyegate announces $3.77 mln registered direct offering (NASDAQ:EYEG)
www.reuters.com - June 27 at 4:52 PM
feeds.benzinga.com logo9 Biggest Mid-Day Losers For Monday (NASDAQ:EYEG)
feeds.benzinga.com - June 27 at 2:48 PM
streetinsider.com logoEyegate Pharma (EYEG) Enters $3.8M Common Stock Registered Direct Offering - StreetInsider.com (NASDAQ:EYEG)
www.streetinsider.com - June 27 at 9:25 AM
reuters.com logoBRIEF-Eyegate Pharmaceuticals files for mixed shelf of up to $100 mln - SEC filing - Reuters (NASDAQ:EYEG)
www.reuters.com - June 27 at 9:25 AM
biz.yahoo.com logoEYEGATE PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equi (NASDAQ:EYEG)
biz.yahoo.com - June 27 at 8:06 AM
finance.yahoo.com logo8:04 am Eyegate Pharmaceuticals to sell 441K shares of common stock at $2.25/share and 2776.5 shares of Series A Convertible Preferred Stock to an institutional investor in an ~$3.77 mln direct offering (NASDAQ:EYEG)
finance.yahoo.com - June 27 at 8:04 AM
finance.yahoo.com logoEyeGate Announces $3.77 Million Registered Direct Offering (NASDAQ:EYEG)
finance.yahoo.com - June 27 at 8:00 AM
News IconEyegate Pharmaceuticals Incorporated (NASDAQ:EYEG) Sellers Covered 22.05% of Their Shorts - Press Telegraph (NASDAQ:EYEG)
presstelegraph.com - June 26 at 4:30 PM
investornewswire.com logoStrong Sell Calls Recommendations For Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) At 0 - Investor Newswire (NASDAQ:EYEG)
www.investornewswire.com - June 26 at 4:30 PM
News IconShare Volatility Check for: Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) - Press Telegraph (NASDAQ:EYEG)
presstelegraph.com - June 26 at 9:52 AM
biz.yahoo.com logoEYEGATE PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a (NASDAQ:EYEG)
biz.yahoo.com - June 22 at 4:16 PM
investornewswire.com logoStrong Buy Calls Count For Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) At 4 - Investor Newswire (NASDAQ:EYEG)
www.investornewswire.com - June 19 at 4:42 PM
News IconMacular Edema Therapeutic Pipeline Review Report H1 2016 (NASDAQ:EYEG)
www.medgadget.com - June 14 at 9:48 AM
investornewswire.com logoTrend Of Rating Given To Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) - Investor Newswire (NASDAQ:EYEG)
www.investornewswire.com - June 12 at 4:52 PM
News IconMaxim Group Reiterates “Buy” Rating for Eyegate Pharmaceuticals Inc (EYEG) - Let Me Know About This (NASDAQ:EYEG)
www.lmkat.com - June 3 at 11:06 PM
finanznachrichten.de logoEYEGATE PHARMACEUTICALS INC (NASDAQ:EYEG)
www.finanznachrichten.de - June 2 at 5:08 PM
finance.yahoo.com logoEYEG: Positive Cataract Surgery Results. Pivotal Study Could Commence By Year-End (NASDAQ:EYEG)
finance.yahoo.com - June 2 at 3:45 PM
nasdaq.com logoEyeGate Announces Encouraging Interim Data from Phase 1b/2a Clinical Trial of EGP-437 for Treatment (NASDAQ:EYEG)
www.nasdaq.com - June 1 at 11:12 PM

Social

Eyegate Pharmaceuticals (NASDAQ:EYEG) Chart for Friday, August, 26, 2016


Last Updated on 8/26/2016 by MarketBeat.com Staff